CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index; 9 of the 17 sources its claims cite were checked for support.
Abstract
BACKGROUND: . METHODS: After conducting preclinical in vitro and in vivo studies, we evaluated the safety and pharmacodynamic effects of single escalating doses of NTLA-2001 in six patients with hereditary ATTR amyloidosis with polyneuropathy, three in each of the two initial dose groups (0.1 mg per kilogram and 0.3 mg per kilogram), within an ongoing phase 1 clinical study. RESULTS: after a single dose. Serial assessments of safety during the first 28 days after infusion in patients revealed few adverse events, and those that did occur were mild in grade. Dose-dependent pharmacodynamic effects were observed. At day 28, the mean reduction from baseline in serum TTR protein concentration was 52% (range, 47 to 56) in the group that received a dose of 0.1 mg per kilogram and was 87% (range, 80 to 96) in the group that received a dose of 0.3 mg per kilogram. CONCLUSIONS: . (Funded by Intellia Therapeutics and Regeneron Pharmaceuticals; ClinicalTrials.gov number, NCT04601051.).
Overview
CoChat Summary
TL;DR
In six patients with hereditary ATTR amyloidosis with polyneuropathy, single intravenous doses of NTLA-2001, a CRISPR-Cas9 lipid nanoparticle therapy, produced dose-dependent reductions in serum TTR protein at day 28 and only mild adverse events. This interim phase 1 study provides early clinical proof of concept for in vivo CRISPR-Cas9 gene editing.
Key findings
- At day 28, mean reduction from baseline in serum TTR protein concentration was 52% (range, 47 to 56) in the 0.1 mg/kg group and 87% (range, 80 to 96) in the 0.3 mg/kg group.
- Adverse events occurred in three of six patients and were all grade 1 (mild); no serious adverse events were observed. One patient had a grade 1 infusion-related reaction, and increased d-dimer levels in five of six patients returned to baseline by day 7.
- Preclinical studies showed durable TTR knockout after a single dose: in primary human hepatocytes, NTLA-2001 had EC50 0.05 to 0.15 nmol/L and EC90 0.17 to 0.67 nmol/L, with ≥93.7% TTR editing and ≥95% reduction in TTR protein production; in cynomolgus monkeys, a single dose of Cyn-LNP at 3 or 6 mg/kg produced maximum whole-liver gene editing of 73% and >94% reduction in serum TTR protein sustained over 12 months.
Methods
- Interim results from two initial dose groups of a two-part, global, phase 1, open-label, multicenter study: six patients with hereditary ATTR amyloidosis with polyneuropathy received a single intravenous dose of NTLA-2001 at 0.1 mg/kg or 0.3 mg/kg (three patients each) between November 2020 and April 2021.
- Key eligibility included age 18 to 80 years, polyneuropathy due to hATTR amyloidosis with or without cardiomyopathy, body weight 50 to 90 kg, and lack of access to approved ATTR treatments; prior TTR stabilizers were permitted after washout.
- Serum TTR protein was measured by validated enzyme-linked immunosorbent assay at baseline and weeks 1, 2, and 4; analyses were descriptive, comparing baseline with day 28 as mean percentage change and range. Preclinical work included primary human hepatocytes, transgenic mice, and cynomolgus monkeys.
Limitations
- The paper states that the study involves a very small number of patients with limited follow-up to date, and that continued serial measurements are planned to confirm durability. It also states that these are interim results from the first two dose groups in an ongoing dose-escalation study.
- Evident from the text: the clinical portion is open-label with no control group, uses descriptive analyses only, reports safety and pharmacodynamic effects through day 28, and does not report clinical outcomes such as disease progression, quality of life, or mortality.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
7 Valid · 1 Not valid · 5 Not checked · 56 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“TTR, which has a normal physiological role in vitamin A transport. 31”
What the sources say
- Supportedcites [31] 31. Müller ML, Butler J, Heidecker B. Emerging therapies in transthyretin amyloidosis - a new wave of hope after years of stagnancy? Eur J Heart Fail 2020; 22: 39-53. source
The Introduction states that TTR physiologically transports retinol-binding protein. The Therapeutic antisense oligonucleotides section links this function to vitamin A levels, supporting the paraphrase that TTR normally plays a role in vitamin A transport. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“but are limited by the requirement for long-term administration to maintain TTR knockdown.”
What the sources say
- Partly supportedcites [12] 12. Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 2018; 379: 11-21. sourceExperimental — accuracy not yet measured
The Trial Design and Regimens section reports patisiran infusions every three weeks for 18 months, and Pharmacodynamics reports sustained TTR reduction during that period. The paper does not establish that long-term administration is required to maintain knockdown after treatment stops, or that this limitation applies to current ATTR treatments generally. (LLM, conf=0.82)
- Not checked — no full text of the sourcecites [13] 13. Adams D, Polydefkis M, GonzálezDuarte A, et al. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an openlabel extension study. Lancet Neurol 2021; 20: 49-59. source
- Partly supportedcites [14] 14. Solomon SD, Adams D, Kristen A, et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. Circulation 2019; 139: 431-43. sourceExperimental — accuracy not yet measured
The Methods (Study Design and Treatment; page unavailable) report patisiran infusions every three weeks for 18 months, and the introductory passage describes its reduction of TTR protein. The paper does not establish that long-term administration is required to maintain TTR knockdown or characterize that requirement as a limitation of current ATTR treatments generally. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“More extensive TTR knockdown is associated with greater improvement in neuropathic end points in patients with hATTR polyneuropathy. 12”
What the sources say
- Partly supportedcites [12] 12. Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 2018; 379: 11-21. sourceExperimental — accuracy not yet measured
The Primary End Point section reports a correlation between the degree of TTR reduction and change in mNIS+7, a composite neuropathy measure, at 18 months. The paper reports improvements in other end points, but our copy does not link the extent of knockdown to improvement across those end points. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“circulating TTR is produced almost entirely (>99%) within the liver, 2”
What the sources say
- Partly supportedcites [2] 2. Gertz MA, Benson MD, Dyck PJ, et al. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol 2015; 66: 2451-66. sourceExperimental — accuracy not yet measured
The section labeled “Diagnosis and Classification” says TTR is synthesized primarily in the liver, supporting the liver as its main source. It does not give the claimed >99% figure for circulating TTR. No page number is available in our copy. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Inotersen is associated with serious side effects, including glomerulonephritis and decreased platelet counts. 17”
What the sources say
- Supportedcites [17] 17. Gertz MA, Scheinberg M, Waddington-Cruz M, et al. Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-medi- - ated amyloidosis. Expert Rev Clin Pharmacol 2019; 12: 701-11. source
The Safety and tolerability section (p. 9) reports decreased platelet counts and glomerulonephritis in patients receiving inotersen, including severe cases. The Regulatory affairs section (p. 9) states that the US approval carries a black box warning for increased risks of thrombocytopenia and glomerulonephritis. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
43 more claims · 1 with their cited sources checked
Create a free account to see all 69 claims and every source verdict.
- Probably not a substantial claim. 11
- It may state two separate claims as one. 15
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“which has already lead to investigational new drugs in clinical trials (NCT04601051)”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Gillmore et al., 2021
The cited source says what the claim attributes to it.
In the citing paper
“Ionizable lipid nanoparticles (LNPs) are a promising non-viral delivery platform for mRNA nanomedicines (13, 14) that have been used to deliver siRNA and CRISPR-based gene editing therapies to the liver in postnatal mouse, non-human primate, and clinical studies with encouraging results (15–18).”
From Ionizable Lipid Nanoparticles for Therapeutic Base Editing of Congenital Brain Disease (2023) · cites this paper as [17]
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716153 · Cited by 3,047
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
Maurer, M. S., Schwartz, J. H., Gundapaneni, B., Elliott, P. M., Merlini, G., Waddington-Cruz, M., Kristen, A. V., Grogan, M., Witteles, R., Damy, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805689 · Cited by 2,857
Bae, S., Park, J., & Kim, J.-S. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu048 · Cited by 2,339
GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases
Tsai, S. Q., Zheng, Z., Nguyen, N. T., Liebers, M., Topkar, V. V., Thapar, V., Wyvekens, N., Khayter, C., Iafrate, A. J., Le, L. P., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3117 · Cited by 2,268
Li, H., Yang, Y., Hong, W., Huang, M., Wu, M., & Zhao, X. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0089-y · Cited by 1,715
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
Akinc, A., Maier, M. A., Manoharan, M., Fitzgerald, K., Jayaraman, M., Barros, S., Ansell, S., Du, X., Hope, M. J., Madden, T. D., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0591-y · Cited by 1,636
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
Benson, M. D., Waddington-Cruz, M., Berk, J. L., Polydefkis, M., Dyck, P. J., Wang, A. K., Planté-Bordeneuve, V., Barroso, F. A., Merlini, G., Obici, L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716793 · Cited by 1,452
Self-citationCRISPR–Cas9 genome editing induces a p53-mediated DNA damage response
Haapaniemi, E., Botla, S., Persson, J., Schmierer, B., & Taipale, J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0049-z · Cited by 1,264
Cited by
Items 1,201–1,300 of 1,725
Wang, Z., Cheng, B., Tkaczyk, C., Newton, M., Cui, S., Andreiuk, B., Saha, S., Khan, S., Chen, C. H., Yang, B., et al. (2026) · AAPS Open · doi:10.1186/s41120-026-00147-5 · Cited by 2
Ethical and Regulatory Considerations for Developing Gene Therapies Involving Genome Editing
Gouda, P., Cohen, L. W., Berelowitz, K., Bollinger, J. M., Bruno, J., Cehelsky, J. E., Charo, R. A., Harrop, J., Kahn, J., McGuire, A., et al. (2026) · Human Gene Therapy · doi:10.1177/10430342261430765 · Cited by 2
“18 The concept of using gene therapy for risk reduction is more nuanced, likely re fl ective of the nature/severity of the disease being prevented, the risk of disease progression or occurrence, and currently available therapies.”
Self-citationMengistu, G. (2026) · The Journal of Gene Medicine · doi:10.1002/jgm.70091 · Cited by 5
Clinical safety and tolerability of in vivo gene editing drug ART001 for ATTR amyloidosis
Jiang, Y., Huang, L. H., Qiu, H., Yang, S., Tao, J., Chen, R., & Hao, Y. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1783921 · Cited by 3
“NTLA-2001 has been advanced to Phase III trials, underscoring the therapeutic potential and feasibility of this strategy in clinical settings (10, 13).”
Streiber, M., Schubert, U. S., & Traeger, A. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115023 · Cited by 7
Wen, M., Li, J., Xu, S., Li, W., Wang, S., Guo, Z., Chen, J., & He, L. (2026) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2026.05.019 · Cited by 2
Nanotechnology-mediated precision delivery of mRNA
Deng, H., Li, L., Zhao, C., Wang, Z., Xiao, Y., Huang, P., Siegwart, D. J., & Chen, X. S. (2026) · Nature Materials · doi:10.1038/s41563-026-02623-5 · Cited by 7
Guidelines for the management of hereditary ATTR amyloidosis 2026
Sekijima, Y., Ueda, M., Berk, J. L., Obici, L. P., Witteles, R. M., Planté‐Bordeneuve, V., Weiler, M., Fontana, M., Waddington‐Cruz, M., Coelho, T., et al. (2026) · Amyloid · doi:10.1080/13506129.2026.2695368 · Cited by 5
“Repair by non-homologous end joining introduces frameshift variants that disrupt the coding sequence, leading to durable suppression of TTR production [40].”
Self-citationMo, Y., & Zheng, G. (2026) · ACS Nano · doi:10.1021/acsnano.6c09354 · Cited by 4
Weiler, M., Dohrn, M. F., Gingele, S., Skripuletz, T., Schilling, M., Hagenacker, T., Hund, E., Sachau, J., Baron, R., Pernice, H. F., et al. (2026) · Neurological Research and Practice · doi:10.1186/s42466-026-00521-4 · Cited by 3
“In vivo CRISPR-Cas9 gene editing targeting hepatic TTR production has demonstrated profound and durable TTR knockdown in early-phase studies, raising the prospect of one-time therapeutic interventions [85].”
She, L., Liang, Z., Zou, Q., & Huo, Y. (2026) · ACS Synthetic Biology · doi:10.1021/acssynbio.6c00386 · Cited by 2
Cell programming to protect the ischemic heart and limb
Brittan, M., & Zimmermann, W. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.09.007 · Cited by 2
How the amyloid fibril has unraveled: lessons for nephrology
Leung, N. (2021) · Kidney International · doi:10.1016/j.kint.2021.10.024 · Cited by 2
Pereira, E. L. R., Feio, D. C. A., Tavares, J. P. L., Morikawa, N. M., Deus, D. F., Vital, C. G., Tavares, E. R., & Maranhão, R. C. (2022) · Journal of Neuro-Oncology · doi:10.1007/s11060-022-04028-1 · Cited by 3
“Recently, nanoparticles resembling LDE in structure, and having ability to target LDL receptors using apo E as ligand have been used to carry oligonucleotides and other molecules destined to gene therapy [48].”
BackgroundApplication of synthetic biology in bladder cancer
Ding, M., Lin, J., Qin, C., Wei, P., Tian, J., Lin, T., & Xu, T. (2022) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002344 · Cited by 3
“To date, clinical trials based on CRISPR/Cas9 gene editing have been carried out in transthyretin amyloidosis,([40]) sickle cell disease and b-thalassemia,([41]) HIV and acute lymphocytic leukemia.”
BackgroundIn vivo gene therapy with CRISPR–Cas9: A promising therapeutic strategy to cure inherited diseases
Li, F., Wang, T., & Cheng, Q. (2022) · MedComm – Future Medicine · doi:10.1002/mef2.26 · Cited by 2
Gao, J., Owusu-Ansah, A., Yang, A. Y., Yim, E., McDermott, D. H., Jacobs, P., Majumdar, S., Choi, U., Sweeney, C. L., Malech, H. L., et al. (2023) · Blood · doi:10.1182/blood.2022019142 · Cited by 10
Yao, Y., Ko, Y., Grasman, G., Raymond, J. E., & Lahann, J. (2023) · Beilstein Journal of Nanotechnology · doi:10.3762/bjnano.14.30 · Cited by 2
Emerging Targeted Therapies for Inherited Cardiomyopathies and Arrhythmias
Ryan, T. L., & Roberts, J. D. (2023) · Cardiac Electrophysiology Clinics · doi:10.1016/j.ccep.2023.04.006 · Cited by 3
A critical view of the revolution of precision medicine: genetics, epigenetics, sex, and gender
Glezerman, M., Ciechanover, A. J., & Legato, M. J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-823937-7.00004-3 · Cited by 3
Adebayo, A. L., Rowan, K. E., Sanchorawala, V., Boedicker, M. N., & Boedicker, D. D. (2023) · MedEdPublish · doi:10.12688/mep.19631.1 · Cited by 3
“, 2017), which result in life-threatening organ damage, morbidity, and mortality (Gillmore et al., 2021; McCausland et al., 2018).”
BackgroundA Primer on Gene Editing: What Does It Mean for Pathologists?
Cushman‐Vokoun, A. M., Schmidt, R. J., Hiemenz, M., Fung, M. K. Y., Zhang, B. M., Bradshaw, G., Gandhi, M. J., Yao, J., Yohe, S. L., Beckman, A. K., et al. (2023) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2022-0410-cp · Cited by 2
Perspectives of genetic management strategy for inherited cardiovascular diseases in China
Zhang, Y., Zheng, Y., Dai, M., Zhou, K., Fu, L., Guo, Y., He, Y., Li, F., Gao, R., Zhang, D., et al. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002804 · Cited by 3
“[6] As mentioned previously, precise gene editing can be realized through the homology-directed repair (HDR) pathway, which is the most versatile means through which nucleases can insert, delete, or replace the desired sequences at a target site using an exogenous donor DNA template.”
BackgroundAdvanced Formulation Approaches for Emerging Therapeutic Technologies
Allahham, N., Colic, I., Rayner, M., Gurnani, P., Phillips, J. B., Rahim, A. A., & Williams, G. R. (2023) · Handbook of experimental pharmacology · doi:10.1007/164_2023_695 · Cited by 3
Self-citationStandardising Care and Treatment of Transthyretin Amyloid Cardiomyopathy
Fontana, M., Porcari, A., & Hawkins, P. N. (2023) · Global Heart · doi:10.5334/gh.1275 · Cited by 2
Self-citationInhalable Therapies for the Heart
Hulot, J., & Kupatt, C. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.10.028 · Cited by 2
CRISPR: the Janus god of modern science
Khare, P., Mandal, S., Verma, A. K., Parashar, D., Jadhav, K., & Gupta, S. K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-91808-4.00006-7 · Cited by 2
Li, B., Li, Q., Qi, Z., Li, Z., Yan, X., Chen, Y., Xu, X., Pan, Q., Chen, Y., Huang, F., et al. (2024) · Angewandte Chemie · doi:10.1002/ange.202316323 · Cited by 2
Current status of hemophilia gene therapy
Kashiwakura, Y. (2024) · Japanese Journal of Thrombosis and Hemostasis · doi:10.2491/jjsth.35.60 · Cited by 2
Chen, P. (2024) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16528 · Cited by 3
“49,60 Delivery of lipid nanoparticles containing gene-guided RNA and Cas9 RNA to the liver has entered into early phase clinical trial, 61 indicating a feasibility for in vivo study.”
BackgroundTreatment of ATTR Amyloidosis: From Stabilizers to Gene Editing
Porcari, A., Maurer, M. S., & Gillmore, J. D. (2024) · Springer eBooks · doi:10.1007/978-3-031-51757-0_21 · Cited by 5
Self-citationHereditary transthyretin amyloidosis presenting with prominent autonomic dysfunction
McCullagh, M., Hughes, S., Canning, A., et al. (2024) · Practical Neurology · doi:10.1136/pn-2023-004048 · Cited by 2
Self-citationPriyanka, P., Raymandal, B., & Mondal, S. (2024) · ChemMedChem · doi:10.1002/cmdc.202400244 · Cited by 2
A Nanobody Toolbox for Recognizing Distinct Epitopes on Cas9
Boylan, J. M., Shrem, R. A., Vallecillo-Viejo, I. C., Duvall, C. L., Wadzinski, B. E., & Spiller, B. W. (2024) · Journal of Molecular Biology · doi:10.1016/j.jmb.2024.168836 · Cited by 2
Zaidel, E. J., Song, S., Sterba, J. J., Piccinato, A., Ramos, M. C., & Cacia, S. L. (2024) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/17539447241295957 · Cited by 2
Genome editing technology and medical applications
Wang, L., Zhou, B., & Li, D. (2024) · Science China Life Sciences · doi:10.1007/s11427-024-2773-3 · Cited by 3
“The combination of lipid nanoparticles (LNPs) and CRISPR-expressing mRNA was employed, partially because the large size of Cas9 complicates the use of rAAV for delivery (Gillmore et al., 2021).”
Unfolding the Link Between Transthyretin Stability and Survival
Angueira, A. R., Abramowitz, S. A., & Levin, M. G. (2024) · JAMA Cardiology · doi:10.1001/jamacardio.2024.4112 · Cited by 2
Islands of genomic stability in the face of genetically unstable metastatic cancer
Bowland, K., Lai, J., Skaist, A. M., Zhang, Y., Teh, S. S. K., Roberts, N. J., Thompson, E., Wheelan, S. J., Hruban, R. H., Karchin, R., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0298490 · Cited by 3
“Also, in vivo delivery of CRISPR agents is still under investigation by many researchers [28] and much optimization is needed [29].”
Advancements in Cardiac Amyloidosis Treatment
Arabi, T. Z., Shaik, A., El-Shaer, A., Tamimi, O. A., Ahmed, E. N., Alabdaljabar, M. S., Safdar, A., & Mushtaq, A. H. (2024) · Biomedicines · doi:10.3390/biomedicines13010079 · Cited by 3
Vutrisiran for ATTR Amyloidosis with Cardiomyopathy
Merlini, G. (2025) · New England Journal of Medicine · doi:10.1056/nejme2411602 · Cited by 2
Allele-specific electrical genotyping for diagnosis of transthyretin amyloidosis
Tayyab, M., Gandotra, N., Sui, J., Scharfe, C., & Javanmard, M. (2025) · Communications Engineering · doi:10.1038/s44172-025-00385-7 · Cited by 2
Amyloidosis of the heart: pathophysiology, diagnosis, and treatment
Wang, A. Y.-Y., Mahmoud, U., Feldman, J. M., Pan, S., Aronow, W. S., & Jain, D. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2480254 · Cited by 3
“A study evaluated the use of NTLA-2001, a gene-editing therapeutic agent based on the CRISPR-Cas9 system, in patients with ATTRv amyloidosis with poly-neuropathy [32,49].”
InfluentialMorris, K. F., DeSalvo, J., Deanparvar, I., et al. (2025) · Biophysica · doi:10.3390/biophysica5020016 · Cited by 2
Chen, H., Tian, Y., Zhang, J., et al. (2025) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-025-03736-x · Cited by 2
“…advancements in treatment have been made, particularly with CRISPR-based TTR silencing therapies like NTLA-2001, which has demonstrated promising results in clinical trials by significantly reducing serum TTR levels through targeted gene editing while maintaining a favorable safety profile [31].”
Park, S. Y., Feng, Z., Choi, S. H., Zhang, X., Tang, Y., Gasser, G. N., Richart, D., Yuan, F., Qiu, J., Engelhardt, J. F., et al. (2025) · Human Gene Therapy · doi:10.1089/hum.2024.260 · Cited by 3
Impact of Vutrisiran on Functional Capacity and Quality of Life in ATTR Cardiomyopathy
Siddiqi, O. K., Ruberg, F. L., & Gopal, D. M. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.03.537 · Cited by 2
Hussain, B., Duhan, S., Patel, B., Chang, Y., Hamza, M., Najam, M., Cheema, M. S., Karamat, M., Mir, J., Keisham, B., et al. (2025) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2025.103129 · Cited by 5
Westarp, P., Keller, T., Brand, J. S., Horvat, S., Albrecht, K., Beisel, C. L., & Gröll, J. (2025) · Discover Nano · doi:10.1186/s11671-025-04316-5 · Cited by 2
“LNPs are the most widely used particles and were used in the first successful systemic in vivo delivery of Cas9 mRNA and sgRNA in humans for treating transthyretin amyloidosis [28].”
Liver-Directed Molecular Therapies
Asp, P., Małachowska, B., Guha, C., & Roy‐Chowdhury, J. (2025) · Clinics in Liver Disease · doi:10.1016/j.cld.2025.06.001 · Cited by 3
Central nervous system involvement in cardiac amyloidosis: Redefining the heart‐brain axis
Giamundo, D. M., Cassataro, G., Ministrini, S., & Stämpfli, S. F. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70122 · Cited by 2
Cardiac amyloidosis: a clinical and pathological review
Maleszewski, J. J. (2022) · Diagnostic histopathology · doi:10.1016/j.mpdhp.2022.02.001 · Cited by 2
Exploiting HIV‐1 tropism to target CD4+ T cells for CRISPR
Heeren, J. J. F. (2021) · Immunology and Cell Biology · doi:10.1111/imcb.12487 · Cited by 2
Recent Scientific Breakthroughs Applying CRISPR Gene Editing in Neurological Disorders
Assadi-Khansari, M., & McGill, L. P. (2021) · Delaware Journal of Public Health · doi:10.32481/djph.2021.12.004 · Cited by 2
Kararoudi, M. N., Alsudayri, A., Hill, C. L., et al. (2022) · Frontiers in Genome Editing · doi:10.3389/fgeed.2022.781531 · Cited by 2
“Cas9 gene editing has been introduced into the clinic and promising outcomes have been reported (Gillmore et al., 2021).”
BackgroundHospital-Based RNA Therapeutics
Damase, T. R., Sukhovershin, R. A., Zhang, M., Kiss, D., & Cooke, J. P. (2022) · RNA technologies · doi:10.1007/978-3-031-08415-7_4 · Cited by 5
Gene Editing in Human Haematopoietic Stem Cells for the Treatment of Primary Immunodeficiencies
Bahal, S., Karaxhuku, K., & Santilli, G. (2022) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-022-00618-x · Cited by 2
“More recently a clinical trial for transthyretin amyloidosis has disclosed the full potential of the Cas9 ‘hit and run’ approach to knock out the mutated misfolded transthyretin in the liver [20].”
BackgroundManaging New Technology When Effective Control is Lost: Facing Hard Choices With CRISPR
Zimbelman, J. (2022) · Journal of Religious Ethics · doi:10.1111/jore.12406 · Cited by 2
The CRISPR Patent Ruling and Implications for Medicine
Paradise, J. K. (2023) · JAMA · doi:10.1001/jama.2022.24986 · Cited by 2
New CRISPR Technology for Creating Cell Models of Lipoprotein Assembly and Secretion
Anaganti, N., Chattopadhyay, A., Filippo, M. D., & Hussain, M. M. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01095-1 · Cited by 2
A Brief History of Amyloidosis
Giorgetti, A., Pucci, A., & Aimo, A. (2024) · Springer eBooks · doi:10.1007/978-3-031-51757-0_3 · Cited by 3
Oxidative damage in immunoglobulin light chain and transthyretin cardiac amyloidosis – a closer look
Cavallone, E., Mousavi, A. H., Biolè, C., Nangeroni, G., Chinaglia, A., & Bianco, M. (2024) · Redox Experimental Medicine · doi:10.1530/rem-24-0001 · Cited by 3
Thérapie génique in vivo : une approche modulaire
Jordan, B. (2024) · médecine/sciences · doi:10.1051/medsci/2024093 · Cited by 2
Gene editing in patients with amyloidosis
Lim, G. B. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00599-0 · Cited by 2
Bouvenot, G. (2022) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2022.02.005 · Cited by 8
Soltaninejad, H., Khoshandam, M., Hamidieh, A. A., & Hosseinkhani, S. (2022) · Authorea · doi:10.22541/au.165268627.74823408/v1 · Cited by 1
In Through the Out Door: Editas' CEOs Grasp Opportunities Amidst Challenges
Philippidis, A. (2022) · GEN Biotechnology · doi:10.1089/genbio.2022.29030.aph · Cited by 2
Functional mRNA delivery to hematopoietic stem and progenitor cells in vivoPreprint
Álvarez, D., Masse‐Ranson, G., Sedimbi, S. K., Wisti, P., Rodriguez, L., Santana, J., Manning, T., Towner, T., Geilich, B., Mihai, C., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.12.15.520650 · Cited by 4
“Use of LNP to deliver mRNA encoding either therapeutic proteins (24) or gene editing tools (13) to HSC in vivo would avoid the need for HSC collection, ex vivo culture, and toxic patient conditioning.”
BackgroundEditorial: Ex-vivo and in-vivo genome engineering for metabolic and neurometabolic diseases
Colella, P., Meneghini, V., Baldo, G., & Gomez‐Ospina, N. (2023) · Frontiers in Genome Editing · doi:10.3389/fgeed.2023.1248904 · Cited by 2
“, 2019), a form of inherited blindness, and Transthyretin Amyloidosis (ATTR), a lethal cardiomyopathy (Gillmore et al., 2021).”
BackgroundInfluentialPorcari, A., Sinagra, G., & Gillmore, J. D. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1232212 · Cited by 2
Self-citationIn vivo expansion of gene-targeted hepatocytes through transient inhibition of an essential genePreprint
Giorgi, M. D., Park, S. H., Castoreno, A. B., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.07.26.550728 · Cited by 2
“The HDR reads were categorized into four subtypes: (1) HDR at both the 5’ and 3’ ends (HDR), (2) 5’HDR with 3’NHEJ (5’HDR-3’NHEJ), (3) HDR with partial truncation of TdTomato HDR(-Td) - and (4) 5’HDR(-Td)-3’NHEJ (Fig.”
BackgroundMethodInfluentialRNA Interference and Neuromuscular Diseases: A Focus on Hereditary Transthyretin Amyloidosis
Ceccanti, M., & Inghilleri, M. (2023) · Current Gene Therapy · doi:10.2174/1566523223666230913110011 · Cited by 3
Choi, D. E., Shin, J. W., Zeng, S., Hong, E. P., Jang, J.-H., Loupe, J. M., Wheeler, V. C., Stutzman, H. E., Kleinstiver, B. P., & Lee, J. (2023) · eLife · doi:10.7554/elife.89782.1 · Cited by 2
Scalable assessment of genome editing off-targets associated with genetic variantsPreprint
Lin, J., Nguyen, M. A., Lin, L. Y., Zeng, J., Verma, A., Neri, N. R., da Silva, L. F., Mucci, A., Wolfe, S. A., Shaw, K. L., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.07.24.605019 · Cited by 4
“…background indel percentage, although comparable to established methods, surpasses the thresholds commonly used in the literature to distinguish relevant off-target editing events that would require risk assessment as part of preclinical assessment of a gene editing therapeutic candidate 25,30,31 .”
ResultWorthington, A. K., Borges, B., Echeverri, E. S., Zada, F. M., Lum, T., Davis, A., Jia, K., Perez, B., Graveson, A., Oder, D., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.12.652147 · Cited by 2
“In utero and postnatal injection were dosed with same mg/kg of LNP based on previously published embryonic weights of C57Bl6 mice 14 and weights at birth.”
Yi, Z., Ma, N., & Ao, Y. (2025) · Biology · doi:10.1101/2025.06.11.658833 · Cited by 3
Programmable pathway profiles reveal signaling principles of TGF-β superfamily receptorsPreprint
Gu, B., Linton, J. M., Hendrickson, B. G., Li, H., Hadas, R., Manella, G., Gregrowicz, J., Anggito, B., Lu, R., & Elowitz, M. B. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.15.659618 · Cited by 3
First in man: gene editing for the treatment of transthyretin amyloidosis
Liuzzo, G., & Patrono, C. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab542 · Cited by 1
Bachtarzi, H. (2022) · Regenerative Medicine · doi:10.2217/rme-2021-0177 · Cited by 1
Chen, J., & Tang, G. (2023) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001471 · Cited by 1
Update on Amyloid Polyneuropathy and Treatment
Zivkovic, S. A., Avila, J. D., Gallegos-Kattán, C., & Quan, D. (2024) · Current Treatment Options in Neurology · doi:10.1007/s11940-024-00780-z · Cited by 1
Gene editing for HD: Therapeutic prospects
Chen, R. Z., & Vogt, T. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95672-7.00021-2 · Cited by 4
Herrador, L., Yun, S., & González‐Costello, J. (2024) · Medicina Clínica · doi:10.1016/j.medcli.2024.03.005 · Cited by 1
Revolutionizing Cardiac Care: The Role of Gene Therapy in Treating Cardiomyopathy
Desai, D. H., Maheta, D., Agrawal, S. P., Patel, M., Frishman, W. H., & Aronow, W. S. (2024) · Cardiology in Review · doi:10.1097/crd.0000000000000792 · Cited by 3
Genome editing technologies and prospects for their use in biomedicine
Karagyaur, M. N., Primak, A. L., Станиславович, Д. С., Дмитриевич, Б. К., & Makus, J. (2024) · Регенерация органов и тканей. · doi:10.60043/2949-5938-2024-1-54-77 · Cited by 1
Evolving Strategies in Cardiac Amyloidosis
Stein-Merlob, A. F., Swier, R. M., & Vucicevic, D. (2024) · Cardiology Clinics · doi:10.1016/j.ccl.2024.09.006 · Cited by 2
Tafamidis: a transthyretin stabilizer for rare cardiac amyloidosis
Tang, J., Cao, Y., Zhang, J., et al. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23932-8.00029-7 · Cited by 1
Emerging Biopharmaceutical Technologies and Trends
Wood, D. W., & Gierach, I. (2024) · Springer eBooks · doi:10.1007/978-3-031-62007-2_19 · Cited by 1
Nano-enabled pharmacogenomics: revolutionizing personalized drug therapy
Tıwarı, R., Dev, D., Thalla, M., Aher, V. D., Mundada, A. B., Mundada, P. A., & Vaghela, K. (2024) · Journal of Biomaterials Science Polymer Edition · doi:10.1080/09205063.2024.2431426 · Cited by 13
“Taken together, this approach was able to effectively eliminate the mutant gene in cancer cells, and make them respond to chemotherapeutic agents, so this form of nano-enabling gene editing was great potential in overcoming drug resistance [81].”
Die Zukunft der Medizin: ein informierter Blick in die „Glaskugel“
Grgic, I. (2024) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2410-9532 · Cited by 1
Concomitant cardiac amyloidosis and aortic stenosis: update on diagnosis and management
Omer, M. H., Shafqat, A., Zenses, A., Ahmad, O., Alsergani, H., Chetrit, M., Fadel, B. M., Tournoux, F., & Mohty, D. (2024) · Journal of the Heart Valve Society · doi:10.1177/30494826241296676 · Cited by 2
“133,134 is worth noting that a negative family history should not preclude genetic testing because the transmission of TTR variants have incomplete penetrance and the the possibility of missed diagnosis in the parent or death of the parent prior to the development of amyloidosis.”
Advances in Studying the Pathologic Mechanisms and Treatment Strategies of Transthyretin Amyloidosis
Chen, H. X., Liu, R., Luo, S., et al. (2024) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001663 · Cited by 1
“52 Similarly, another gene editing technology using adeno-associated virus based on homing endonucleases revealed remarkable effects, achieving a sustained reduction of more than 95% in the serum levels of TTR compared with base-line in rhesus monkey experiments.”
Crop Improvement Using CRISPR/Cas9 Systems: Advances and Challenges
Shah, S. (2024) · Premier Journal of Plant Biology · doi:10.70389/pjpb.100004 · Cited by 1
Saberi, F., Yousefi-Najafabadi, Z., Shams, F., Dehghan, Z., Ahmadi, S., Pilehchi, T., Noori, E., Esmaeelzadeh, Z., Bazgiri, M., Mohammadi, R., et al. (2025) · Current Gene Therapy · doi:10.2174/0115665232345516241119070150 · Cited by 3
Slattery, S. S., Huo, W., Arif, A., Gordon, J., & Takeuchi, R. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.102944 · Cited by 4
“16,17 Earlier studies have demonstrated that CRISPR-Cas9 can access intracellular HBV DNA to suppress viral transcription and protein expression, 18–23 and two gene editing-based therapies for CHB have recently advanced to clinical trials (NCT06680232; NCT06671093).”
Wu, W., & Wang, Z. (2025) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2025.2517363 · Cited by 3
“[10,11,18], while two studies reported significantly higher incidences (38.9% and 50%, respectively) [9,12].”
InfluentialNugroho, K., Lin, C., Monteiro, C., Coelho, T., Moresco, J. J., Pinto, A. F. M., Powers, E. T., Yates, J. R., Diedrich, J. K., & Kelly, J. W. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125534 · Cited by 2
“A future potential therapeutic strategy (not yet regulatory agency approved) is gene editing, which is being investigated as a strategy to permanently knock out or knock down hepatocyte-synthesized mutant TTR [16].”
Treatment of Cardiac Amyloidosis—Disease Modifying Therapies in ATTR: Pharmacological Point of View
Raccah, B. H. (2025) · Springer eBooks · doi:10.1007/978-3-031-88342-2_16 · Cited by 1
Emerging vesicular nanosystems capable of effectively targeting hepatocytes
Chan, V., Pierre, A. S., Đỗ, T. H., & Li, S. (2025) · Nanomedicine · doi:10.1080/17435889.2025.2534326 · Cited by 2
From pathophysiology to treatment in transthyretin cardiac amyloidosis
Correia-Rodrigues, Â., Ribeiro‐Rodrigues, T., Gonçalves, L. M. M., Almeida, J. P., Ferreira, M. J., & Girão, H. (2025) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2025.07.002 · Cited by 1
Efficient gene disruption with CRISPR–Cas3 in human T cells
Fujii, T., Sakoda, Y., Yoshimi, K., Takeshita, K., Watanabe, S., Iida, R., Obo, T., Yokoyama, K., Tamada, K., & Mashimo, T. (2026) · NAR Cancer · doi:10.1093/narcan/zcag009 · Cited by 1
“Among these, Cas9 has demonstrated robust editing activity in eukaryotic cells and has facilitated the development of novel therapeutic strategies [ 5 , 6 ].”
Metadata
- Authors
- Gillmore, J. D., Gane, E., Taubel, J., Kao, J., Fontana, M., Maitland, M. L., Seitzer, J., O’Connell, D., Walsh, K. R., Wood, K., Phillips, J., Xu, Y., Amaral, A., Boyd, A. P., Cehelsky, J. E., McKee, M. D., Schiermeier, A., Harari, O., Murphy, A., Kyratsous, C. A., Zambrowicz, B., Soltys, R., Gutstein, D. E., Leonard, J., Sepp-Lorenzino, L., & Lebwohl, D.
- Affiliations
- University of Auckland (NZ)
- From the National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital (J.D.G., M.F.) and Richmond Pharmacology, St. George’s University of London (J.T.) — both in London; New Zealand Clinical Research (E.G.), University of Auckland (E.G.), and the Department of Neurology, Auckland City Hospital (J.K.) — all in Auckland, New Zealand; Intellia Therapeutics, Cambridge, MA (M.L.M., J.S., D.O., K.R.W., K.W., J.P., Y.X., A.A., A.P.B., J.E.C., M.D.M., A.S., J.L., L.S.-L., D.L.); and Regeneron Pharmaceuticals, Tarrytown, NY (O.H., A.M., C.A.K., B.Z., R.S., D.E.G.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-08-05
- Volume
- 385
- Issue
- 6
- Pages
- 493-502
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3177445623
- Cited by
- 1,801
- References
- 35
- Citations by year
- 2026: 349 · 2025: 332 · 2024: 368 · 2023: 336 · 2022: 328 · 2021: 84
- FWCI
- 228.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Regeneron Pharmaceuticals
- Intellia Therapeutics
- Topics
- Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- transthyretin amyloidosis, hereditary ATTR amyloidosis, CRISPR/Cas9 genome editing, in vivo gene therapy, prealbumin, polyneuropathy, single ascending dose, pharmacodynamics, safety
- MeSH terms
- Gene Editing, RNA, Guide, CRISPR-Cas Systems, Female, Humans, Infusions, Intravenous, Liposomes, Male, Middle Aged, Prealbumin, RNA, Messenger, RNA, Guide, Kinetoplastida, Gene Transfer Techniques, Amyloid Neuropathies, Familial, Nanoparticles, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-27, under version 3 of the claim definition (prompt extract-v3).
A second model labelled each claim on 2026-09-27 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.



